newsfilter
← Earnings
Earnings Releases·

Lantern Pharma — Third Quarter 2026 Earnings Summary

  • **Financial Results & Liquidity:** Q3 2026 reported net income of $0.7 million ($0.05/share) versus a net loss of $4.2 million in Q3 2025, driven by a $6.0 million non-cash warrant gain; excluding a $2.0 million settlement accrual, operating loss decreased 22% year-over-year to $3.4 million. Cash and equivalents fell to $7.6 million from $10.1 million at year-end 2025, with the company stating substantial doubt exists regarding its ability to continue as a going concern without additional funding.
  • **Capital & Governance:** The company closed a registered direct offering on September 30, 2026, raising approximately $4.0 million in gross proceeds. Management announced the resignation of CEO Panna Sharma and the appointment of CFO David Margrave as Interim CEO, with the Board initiating a search for a permanent CEO.
  • **Clinical & Strategic Outlook:** The HARMONIC™ trial for LP-300 is enrolling in Taiwan and the U.S., with IRB approval anticipated at two additional Taiwan sites in Q4 2026; LP-184 has engaged its first site for a Phase 1b/2 trial in triple-negative breast cancer and has an open Phase 1b/2 trial in bladder cancer. The company plans to pursue periodic capital raises, collaborations, and licensing opportunities for LP-300 in East Asia to extend its operating runway.
Company
LANTERN PHARMA INC
Sector
Healthcare
Industry
Biotechnology